Immunotherapy for the Treatment of Breast Cancer

Current Oncology Reports

Volumn 17, Issue 2, 2015, Pages

  Ernst, Brenda ^a   Anderson, Karen S ^a,b  

^a MAYO CLINIC   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Immunotherapy; Tumor antigen; Tumor immunology; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; ANTHRACYCLINE DERIVATIVE; CANCER VACCINE; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LAPULEUCEL T; MAMMAGLOBIN A; MELANOMA ANTIGEN 3; MONTANIDE ISA 51; MUCIN 1; NELIPEPIMUT S; NY ESO 1 ANTIGEN; PEPTIDE VACCINE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T; TAXANE DERIVATIVE; THERATOPE; TRASTUZUMAB; VIRUS VECTOR; WT1 PROTEIN; ANTINEOPLASTIC AGENT;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; AUTOIMMUNITY; BLADDER CANCER; BREAST CANCER; CANARYPOX VIRUS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; FOWLPOX VIRUS; HUMAN; IMMUNE DYSREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; MEASLES VIRUS; MELANOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; VACCINIA VIRUS; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; IMMUNOTHERAPY; TUMOR MICROENVIRONMENT;

EID: 84923087112     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-014-0426-9     Document Type: Review

References (82)

1. American Cancer Society. Cancer facts and figures. In: American Cancer Society, editor. Atlanta 2014.
2. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer. 2006;94(2):259–67. doi:10.1038/sj.bjc.6602930.
3. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011;11(11):805–12. doi:10.1038/nrc3153.
4. Pockaj BA, Basu GD, Pathangey LB, Gray RJ, Hernandez JL, Gendler SJ, et al. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol. 2004;11(3):328–39.
5. Wang ZX, Cao JX, Wang M, Li D, Cui YX, Zhang XY, et al. Adoptive cellular immunotherapy for the treatment of patients with breast cancer: a meta-analysis. Cytotherapy. 2014;16(7):934–45. doi:10.1016/j.jcyt.2014.02.011.
6. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005;11(3):312–9. doi:10.1038/nm1196.
7. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4(10):762–74. doi:10.1038/nri1457.
8. Carpi A, Nicolini A, Antonelli A, Ferrari P, Rossi G. Cytokines in the management of high risk or advanced breast cancer: an update and expectation. Curr Cancer Drug Targets. 2009;9(8):888–903.
9. Hamidullah, Changkija B, Konwar R. Role of interleukin-10 in breast cancer. Breast Cancer Res Treat. 2012;133(1):11–21. doi:10.1007/s10549-011-1855-x.
10. Markowitz J, Wesolowski R, Papenfuss T, Brooks TR, Carson 3rd WE. Myeloid-derived suppressor cells in breast cancer. Breast Cancer Res Treat. 2013;140(1):13–21. doi:10.1007/s10549-013-2618-7.
11. Iclozan C, Antonia S, Chiappori A, Chen DT, Gabrilovich D. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother. 2013;62(5):909–18. doi:10.1007/s00262-013-1396-8.
12. Melero I, Hirschhorn-Cymerman D, Morales-Kastresana A, Sanmamed MF, Wolchok JD. Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res. 2013;19(5):1044–53. doi:10.1158/1078-0432.ccr-12-2065.
13. Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol. 2014. doi:10.1038/nrclinonc.2014.111. This review paper describes the current application of vaccines in clinical trials including breast cancer.
14. Yao S, Zhu Y, Chen L. Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov. 2013;12(2):130–46. doi:10.1038/nrd3877.
15. LoRusso PM. Mammalian target of rapamycin as a rational therapeutic target for breast cancer treatment. Oncology. 2013;84(1):43–56. doi:10.1159/000343063.
16. Vinayak S, Carlson RW. mTOR inhibitors in the treatment of breast cancer. Oncology (Williston Park). 2013;27(1):38–44. 6, 8 passim.
17. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, et al. mTOR regulates memory CD8 T-cell differentiation. Nature. 2009;460(7251):108–12. doi:10.1038/nature08155.
18. Nam JH. Rapamycin: could it enhance vaccine efficacy? Expert Rev Vaccines. 2009;8(11):1535–9. doi:10.1586/erv.09.115.
19. Baselga J, Campone M, Piccart M, Burris 3rd HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–9. doi:10.1056/NEJMoa1109653.
20. Ascierto ML, Kmieciak M, Idowu MO, Manjili R, Zhao Y, Grimes M, et al. A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat. 2012;131(3):871–80. doi:10.1007/s10549-011-1470-x.
21. Stagg J, Allard B. Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. Ther Adv Med Oncol. 2013;5(3):169–81. doi:10.1177/1758834012475152. This review paper focuses on current use of immunotherapy in triple-negative breast cancer.
22. Hirshfield KM, Ganesan S. Triple-negative breast cancer: molecular subtypes and targeted therapy. Curr Opin Obstet Gynecol. 2014;26(1):34–40. doi:10.1097/gco.0000000000000038.
23. Alexe G, Dalgin GS, Scanfeld D, Tamayo P, Mesirov JP, DeLisi C, et al. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res. 2007;67(22):10669–76. doi:10.1158/0008-5472.can-07-0539.
24. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105–13. doi:10.1200/jco.2009.23.7370.
25. Soliman H. Immunotherapy strategies in the treatment of breast cancer. Cancer Control. 2013;20(1):17–21.
26. Emens LA. Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther. 2012;12(12):1597–611. doi:10.1586/era.12.147.
27. Clive KS, Tyler JA, Clifton GT, Holmes JP, Ponniah S, Peoples GE, et al. The GP2 peptide: a HER2/neu-based breast cancer vaccine. J Surg Oncol. 2012;105(5):452–8. doi:10.1002/jso.21723. Key paper summarizing GP2 characterization studies, clinical trials and GP2 in combination with other vaccines and monoclonal antibodies.
28. Sinn BV, von Minckwitz G, Denkert C, Eidtmann H, Darb-Esfahani S, Tesch H, et al. Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer. Ann Oncol. 2013;24(9):2316–24. doi:10.1093/annonc/mdt162.
29. Mittendorf EA, Clifton GT, Holmes JP, Schneble E, van Echo D, Ponniah S, et al. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol. 2014. doi:10.1093/annonc/mdu211. Key paper summarizing phase I/II results of the E75 HER-2 peptide vaccine.
30. Holmes JP, Gates JD, Benavides LC, Hueman MT, Carmichael MG, Patil R, et al. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer. 2008;113(7):1666–75. doi:10.1002/cncr.23772.
31. Sears AK, Perez SA, Clifton GT, Benavides LC, Gates JD, Clive KS, et al. AE37: a novel T-cell-eliciting vaccine for breast cancer. Expert Opin Biol Ther. 2011;11(11):1543–50. doi:10.1517/14712598.2011.616889.
32. Blixt O, Bueti D, Burford B, Allen D, Julien S, Hollingsworth M, et al. Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. Breast Cancer Res. 2011;13(2):R25. doi:10.1186/bcr2841.
33. Julien S, Picco G, Sewell R, Vercoutter-Edouart AS, Tarp M, Miles D, et al. Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model. Br J Cancer. 2009;100(11):1746–54. doi:10.1038/sj.bjc.6605083.
34. MacLean GD, Reddish M, Koganty RR, Wong T, Gandhi S, Smolenski M, et al. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol Immunother. 1993;36(4):215–22.
35. Miles DW, Towlson KE, Graham R, Reddish M, Longenecker BM, Taylor-Papadimitriou J, et al. A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br J Cancer. 1996;74(8):1292–6.
36. Miles D, Roche H, Martin M, Perren TJ, Cameron DA, Glaspy J, et al. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist. 2011;16(8):1092–100. doi:10.1634/theoncologist. 2010-0307.
37. Ibrahim NK, Murray JL, Zhou D, Mittendorf EA, Sample D, Tautchin M, et al. Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial. J Cancer. 2013;4(7):577–84. doi:10.7150/jca.7028. Trial showing the benefit in combination with endocrine therapy for ER-positive subset.
38. Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A. 2004;101(29):10697–702. doi:10.1073/pnas.0403572101.
39. Kitano S, Tsuji T, Liu C, Hirschhorn-Cymerman D, Kyi C, Mu Z, et al. Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. Cancer Immunol Res. 2013;1(4):235–44. doi:10.1158/2326-6066.cir-13-0068.
40. Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A. 2011;108(40):16723–8. doi:10.1073/pnas.1110814108.
41. Hamai A, Duperrier-Amouriaux K, Pignon P, Raimbaud I, Memeo L, Colarossi C, et al. Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy. PLoS ONE. 2011;6(6):e21129. doi:10.1371/journal.pone.0021129.
42. Page DB, Naidoo J, McArthur HL. Emerging immunotherapy strategies in breast cancer. Immunotherapy. 2014;6(2):195–209. doi:10.2217/imt.13.166. This review paper discusses recent updates in breast cancer immunotherapy research.
43. Theurillat JP, Ingold F, Frei C, Zippelius A, Varga Z, Seifert B, et al. NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T-cell and CD79a + plasmacytic/B-cell infiltration. Int J Cancer. 2007;120(11):2411–7. doi:10.1002/ijc.22376.
44. Thompson JA, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal. 1991;5(5):344–66.
45. Turriziani M, Fantini M, Benvenuto M, Izzi V, Masuelli L, Sacchetti P, et al. Carcinoembryonic antigen (CEA)-based cancer vaccines: recent patents and antitumor effects from experimental models to clinical trials. Recent Patents Anticancer Drug Discov. 2012;7(3):265–96.
46. Vonderheide RH. Universal tumor antigens for cancer vaccination: targeting telomerase for immunoprevention. Discov Med. 2007;7(39):103–8.
47. Parkhurst MR, Riley JP, Igarashi T, Li Y, Robbins PF, Rosenberg SA. Immunization of patients with the hTERT:540–548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res. 2004;10(14):4688–98. doi:10.1158/1078-0432.ccr-04-0325.
48. Yang L, Han Y, Suarez Saiz F, Minden MD. A tumor suppressor and oncogene: the WT1 story. Leukemia. 2007;21(5):868–76. doi:10.1038/sj.leu.2404624.
49. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15(17):5323–37. doi:10.1158/1078-0432.ccr-09-0737. Provides a ranked list of the key antigens in cancer likely to show clinical efficacy.
50. Morita S, Oka Y, Tsuboi A, Kawakami M, Maruno M, Izumoto S, et al. A phase I/II trial of a WT1 (Wilms’ tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Jpn J Clin Oncol. 2006;36(4):231–6. doi:10.1093/jjco/hyl005.
51. Balafoutas D, zur Hausen A, Mayer S, Hirschfeld M, Jaeger M, Denschlag D, et al. Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications. BMC Cancer. 2013;13:271. doi:10.1186/1471-2407-13-271.
52. Tiriveedhi V, Fleming TP, Goedegebuure PS, Naughton M, Ma C, Lockhart C, et al. Mammaglobin-A cDNA vaccination of breast cancer patients induces antigen-specific cytotoxic CD4 + ICOShi T cells. Breast Cancer Res Treat. 2013;138(1):109–18. doi:10.1007/s10549-012-2110-9. Safety study demonstrating clinical benefit of mammaglobin-A cDNA vaccine.
53. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(7):1099–105. doi:10.1200/jco.2009.25.0597.
54. Mohebtash M, Tsang KY, Madan RA, Huen NY, Poole DJ, Jochems C, et al. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res. 2011;17(22):7164–73. doi:10.1158/1078-0432.ccr-11-0649.
55. Scholl S, Squiban P, Bizouarne N, Baudin M, Acres B, Von Mensdorff-Pouilly S, et al. Metastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2. J Biomed Biotechnol. 2003;2003(3):194–201. doi:10.1155/s111072430320704x.
56. Ramos RN, Chin LS, Dos Santos AP, Bergami-Santos PC, Laginha F, Barbuto JA. Monocyte-derived dendritic cells from breast cancer patients are biased to induce CD4 + CD25 + Foxp3+ regulatory T cells. J Leukoc Biol. 2012;92(3):673–82. doi:10.1189/jlb.0112048.
57. Liu T, Song YN, Shi QY, Liu Y, Bai XN, Pang D. Study of circulating antibodies against CD25 and FOXP3 in breast cancer. Tumour Biol. 2014;35(4):3779–83. doi:10.1007/s13277-013-1500-x.
58. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22. doi:10.1056/NEJMoa1001294.
59. Baek S, Kim CS, Kim SB, Kim YM, Kwon SW, Kim Y, et al. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial. J Transl Med. 2011;9:178. doi:10.1186/1479-5876-9-178.
60. Fracol M, Xu S, Mick R, Fitzpatrick E, Nisenbaum H, Roses R, et al. Response to HER-2 pulsed DC1 vaccines is predicted by both HER-2 and estrogen receptor expression in DCIS. Ann Surg Oncol. 2013;20(10):3233–9. doi:10.1245/s10434-013-3119-y.
61. Sharma A, Koldovsky U, Xu S, Mick R, Roses R, Fitzpatrick E, et al. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer. 2012;118(17):4354–62. doi:10.1002/cncr.26734.
62. Koski GK, Koldovsky U, Xu S, Mick R, Sharma A, Fitzpatrick E, et al. A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J Immunother. 2012;35(1):54–65. doi:10.1097/CJI.0b013e318235f512.
63. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. doi:10.1056/NEJMoa1003466.
64. Anderson KS. Tumor vaccines for breast cancer. Cancer Invest. 2009;27(4):361–8. doi:10.1080/07357900802574421.
65. Creelan BC, Antonia S, Bepler G, Garrett TJ, Simon GR, Soliman HH. Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in stage III non-small cell lung cancer. Oncoimmunology. 2013;2(3):e23428. doi:10.4161/onci.23428.
66. Brignone C, Gutierrez M, Mefti F, Brain E, Jarcau R, Cvitkovic F, et al. First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med. 2010;8:71. doi:10.1186/1479-5876-8-71.
67. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319(25):1676–80. doi:10.1056/nejm198812223192527.
68. Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res. 1996;56(11):2479–83.
69. Yee C. Adoptive T, cell therapy: addressing challenges in cancer immunotherapy. J Transl Med. 2005;3(1):17. doi:10.1186/1479-5876-3-17.
70. Vonderheide RH, LoRusso PM, Khalil M, Gartner EM, Khaira D, Soulieres D, et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res. 2010;16(13):3485–94. doi:10.1158/1078-0432.ccr-10-0505.
71. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020–30. doi:10.1200/jco.2013.53.0105.
72. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–33. doi:10.1056/NEJMoa1302369.
73. Xie F, Wang Q, Chen Y, Gu Y, Mao H, Zeng W, et al. Costimulatory molecule OX40/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. Pathol Res Pract. 2010;206(11):735–9. doi:10.1016/j.prp.2010.05.016.
74. Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol. 2009;27(35):5911–8. doi:10.1200/jco.2009.23.3494.
75. Cerullo V, Diaconu I, Kangasniemi L, Rajecki M, Escutenaire S, Koski A, et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther. 2011;19(9):1737–46. doi:10.1038/mt.2011.113.
76. Demaria S, Volm MD, Shapiro RL, Yee HT, Oratz R, Formenti SC, et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res. 2001;7(10):3025–30.
77. Chen G, Gupta R, Petrik S, Laiko M, Leatherman JM, Asquith JM, et al. A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for HER-2+ Metastatic Breast Cancer. Cancer Immunol Res. 2014. doi:10.1158/2326-6066.cir-14-0058. Study combining low-dose chemotherapy, monoclonal antibody, and allogeneic cellular vaccine.
78. Rech AJ, Mick R, Martin S, Recio A, Aqui NA, Powell Jr DJ, et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci Transl Med. 2012;4(134):134ra62. doi:10.1126/scitranslmed.3003330.
79. Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol. 2009;27(28):4685–92. doi:10.1200/jco.2008.20.6789.
80. Trappey Fea. J. Clin. Oncol.2013.
81. Mittendorf. J Clin Oncol. 2014;32:5s.
82. Schneble et al. J Immunol Ther Cancer. 2013;1:236.